Examiners' priority list, a $106.8 million judgment, and the first antisense hepatitis B drug — October 20–26, 2026
A sourced digest of the twenty-two SEC, FDA, and FTC developments from October 20–26, 2026, with the parties, procedural status, money at issue, and the deadlines to calendar.
The week of October 20–26, 2026 produced twenty-two developments across the three agencies: nine from the SEC, nine from the FDA, and four from the FTC.
The SEC's Division of Examinations published the list that will steer every registered firm's next inspection. Behind it came a censure over custody and identity-theft controls, two settled fraud cases and one proposed penny-stock judgment. The FDA approved the first antisense drug for hepatitis B and a once-weekly insulin for children, then released three guidance documents in a single Friday batch. The FTC closed a debt-relief case with a $106.8 million judgment, sued a passport site for impersonating the government, and opened comment on the conditions it attached to Publicis's purchase of LiveRamp.
At a glance
| Agency | Development | Status or amount | Next action |
|---|---|---|---|
| SEC | Fiscal year 2027 examination priorities (Oct. 23) | Eight focus areas for more than 34,000 registered entities, from adviser conflicts to Treasury clearing and tokenization | Map internal testing and document requests to the listed areas. 1 |
| SEC | TAG Associates LLC (Oct. 23) | Censured and fined $175,000 over custody-rule and identity-theft-program failures running from 2014 to 2026 | Penalty due within ten days; audit custody verification and Regulation S-ID procedures. 2 |
| SEC | Benjamin Conde (Oct. 21) | Proposed final judgment over a 2017 penny-stock manipulation; $2,778,821.69 in disgorgement and interest, plus a penny stock bar | Waiting on court approval; deemed satisfied by parallel criminal orders. 3 |
| SEC | Estate of Chirayu Vijay Patel (Oct. 20) | Settled charges over $10 million raised from more than 40 investors; $1,403,095.23 in disgorgement and interest | Waiting on court approval; no admission of the allegations. 4 |
| SEC | Terrance Berland and David Scalzo, Violet Defense Group (Oct. 20) | Settled charges over $13 million raised from 88 investors on inflated 2021 revenue projections; $100,000 penalty each | Waiting on court approval; injunction under Section 17(a)(2). 5 |
| SEC | Interval fund modernization proposal (Oct. 20) | Correction to the October 5 notice, Release Nos. 33-11444, 34-106534 and IC-36351, File No. S7-2026-34 | Comments close December 4, 2026. 6 |
| SEC | Supervisory memorandum with the French AMF (Oct. 20) | Information-sharing framework for advisers and funds; the SEC resumes processing registration applications from AMF-supervised managers | French managers with pending applications should expect processing to restart. 7 |
| SEC | Rules scheduled for Regulatory Flexibility Act review (Oct. 23) | Section 610 review list, File No. S7-2026-37, covering rules with significant impact on small entities | Comments close November 23, 2026. 8 |
| SEC | Transfer agent registrations (Oct. 22) | Notice of intent to cancel registrations of transfer agents believed to be out of business, Release No. 34-106697 | Cancellation any time after December 1, 2026. 9 |
| FDA | Hibsago (bepirovirsen), GSK (Oct. 20) | First antisense oligonucleotide approved for chronic hepatitis B; 24% of patients met the criteria to stop all therapy, against none on placebo | Companion diagnostic authorized; boxed warning for liver injury and low platelets. 10 |
| FDA | Prescription drug use-related software (Oct. 20) | Final guidance separating device-connected apps from standalone ones and fixing when software enters the label | Review app content against the promotional-labeling treatment. 11 |
| FDA | Awiqli (insulin icodec-abae), Novo Nordisk (Oct. 23) | First once-weekly insulin approved for patients aged 10 and older with type 2 diabetes | Prescribers and pharmacists to note the dosing difference from other insulins. Application is Novo Nordisk's, BLA 761326. 1213 |
| FDA | Cadmium action levels in food for children under two (Oct. 23) | Draft guidance setting action levels for cadmium in processed food for babies and young children, Docket FDA-2025-D-4023 | Comments close December 22, 2026. 14 |
| FDA | Preventive controls draft guidance, chapter 12 (Oct. 23) | New draft chapter on control of chemical hazards under the human food preventive controls rule, Docket FDA-2016-D-2343 | Comments close January 21, 2027. 15 |
| FDA | Mandatory cosmetics recalls (Oct. 23) | Final question-and-answer guidance on the agency's cosmetics recall authority, Docket FDA-2025-D-2246 | Test recall procedures against it. 16 |
| FDA | Neuroscience Advancement and Innovation Nexus (Oct. 22) | New program across the drug, biologic and device centers; first initiative covers Alzheimer's prevention | Watch for trial-design and endpoint guidance from the accelerator. 17 |
| FDA | Warning letters posted October 20 | Ten letters with issue dates from September 28 to October 14, including Baxter International, Olympus Medical Systems and Rohto Pharmaceutical | Screen supplier, contractor and client lists against the ten names. 18 |
| FDA | New dietary ingredient notifications (Oct. 20) | Final guidance on the identity and safety information an NDIN submission should carry | Check pending notifications against it. 19 |
| FTC | GovAssist LLC, Entry LLC and Scott Zuckerman (Oct. 22) | Suit filed in the District of Puerto Rico over passport sites that impersonated the government and carried fake reviews | Litigation pending; no relief ordered yet. 20 |
| FTC | Accelerated Debt Settlement Inc. and related entities (Oct. 22) | $106.8 million default judgment entered October 14; industry ban for seven companies and three individuals | Individual stipulated orders filed October 22. 21 |
| FTC | Publicis and LiveRamp (Oct. 23) | Analysis of the consent order published; five years of access, firewall and audit conditions on the $2.2 billion acquisition | Comments close November 23, 2026. 22 |
| FTC | Petition for rulemaking of Jason Plotzker (Oct. 21) | Petition seeking rules on price advertising by penny auction and pay-per-bid operators, Docket FTC-2026-1618 | Comments close November 20, 2026. 23 |
SEC
What examiners will look at this year
The Division of Examinations published its fiscal year 2027 priorities on October 23. The program covers more than 34,000 registered entities: advisers, funds, broker-dealers, self-regulatory organizations, clearing agencies, municipal advisors, transfer agents, funding portals and security-based swap entities. 1
Eight areas carry the weight:
- Adviser fiduciary obligations, conflicts of interest, investment recommendations and compliance programs.
- Retail investor protection in complex, higher-risk and illiquid products.
- Private funds, private credit and other complex strategies.
- Broker-dealer financial responsibility, trading practices, supervision and anti-money-laundering compliance.
- Operational resiliency, cybersecurity and protection of customer information.
- Emerging technologies, including super intelligence and other tools that touch market operations and fraud prevention.
- Market infrastructure changes: Treasury clearing reforms, tokenization and related developments.
- Oversight of self-regulatory organizations and other critical market participants. 1
Two of these are new in substance for most firms. Treasury clearing reform has been a rulemaking story for two years; the priorities put it on the examination side, where the question becomes whether a firm's clearing arrangements and client disclosures match the new structure. Super intelligence is named directly, which tells firms with automated execution, surveillance or advice tooling that the model behind the tool is now part of the examination.
The division says the list marks areas of heightened attention and that its examinations will reach well beyond them. Listed priorities have a habit of turning up in initial document requests.
Keith Cassidy, the division's director, framed the approach as continuous risk assessment across registrants, products and activities. Chairman Paul Atkins called examinations one of the Commission's most important compliance tools. 1
Custody, identity theft and a $175,000 penalty
TAG Associates LLC, a Delaware adviser based in New York, settled charges on October 23 covering twelve years of control failures. 2
From December 2015 to September 2026 the firm failed to obtain independent verification of client funds and securities over which it had custody. It also failed to keep certain securities with a qualified custodian. Both are requirements of the custody rule, Section 206(4) and Rule 206(4)-2 under the Advisers Act. 2
The second half of the order is the part most firms will recognize less easily. From June 2014 to December 2023 TAG violated Rule 201 of Regulation S-ID. It ran no internal review of its written identity theft prevention program and never updated it for red flags it had detected. It also left the program without a board, committee or senior manager overseeing it. 2
TAG consented to a cease-and-desist order, a censure and a $175,000 civil penalty payable within ten days.
Regulation S-ID is the identity theft red flags rule, and it binds advisers as well as broker-dealers. The order describes the failure in operational terms: a written program on file, and nothing done with it since. An annual review that produces a dated memo, a named program owner and evidence that red flags were acted on is what the Commission was looking for.
Three settlements and one proposed judgment
The estate of Chirayu Vijay Patel agreed to pay $1,403,095.23 on October 19, and the Commission announced the settlement the next day. Patel raised about $10 million from more than 40 investors in two offerings between July 2020 and November 2025, one promising fixed returns of 6% a year and the other targeting 20%. 4
The complaint alleges Patel misappropriated about $1.2 million for personal expenses, paid about $1.5 million back to some investors in Ponzi-like payments, and lost more than $7 million trading. Investors received false account statements and false rates of return. The estate settled without admitting the allegations, and the $1,204,597.77 disgorgement plus $198,497.46 interest awaits court approval. 4
Terrance Berland and David Scalzo, former chief executive and former director of Violet Defense Group, raised about $13 million from 88 investors between April and November 2021. The company, a Florida photonics business that has since folded, was described as on track for $15 million to $18 million of 2021 revenue. 5
The complaint says the two men knew by August 2021 that sales and royalty revenue had fallen sharply, and that more than 40% of investor money had gone to a NASCAR team sponsorship by the end of that August. Purchase agreements signed between August and October 2021 still carried assurances that nothing had happened to hurt the company's finances. Each consented to an injunction under Section 17(a)(2) and a $100,000 penalty. 5
Benjamin Conde ran a scheme in Renewable Energy and Power Inc. between March and July 2017. He acquired millions of shares, paid for a boiler-room promotion, and traded in matched and wash orders to create the appearance of an active market while selling into it. Conde pleaded guilty in a parallel criminal case to conspiracy to commit securities fraud. 3
The proposed judgment, filed October 20 in the Eastern District of New York, would permanently enjoin Conde, bar him from penny stocks, and order $1,097,800 in disgorgement plus $1,681,021.69 in prejudgment interest. The $2,778,821.69 total would be treated as satisfied by the restitution and forfeiture orders in the criminal case. The Commission also dropped its claims against two relief defendants, which ends the litigation. 3
Also on the SEC docket
The interval fund modernization proposal went to the Federal Register on October 5 with an error in its dates section. A correction published October 20 restates the deadline: comments close December 4, 2026, under File No. S7-2026-34. Anyone who calendared a different date from the October 5 text should replace it. 6
The Commission and the French Autorité des Marchés Financiers signed a supervisory memorandum on October 20. The agreement covers consultation and information-sharing on advisers, investment companies and investment service providers operating in both countries. Its immediate effect is procedural: the SEC will now process new and pending registration applications from AMF-supervised asset management companies that want to do business in the United States as advisers. 7
A third item is a housekeeping document with a real deadline. The Commission published its annual list of rules scheduled for review under section 610 of the Regulatory Flexibility Act, in File No. S7-2026-37. Comments close November 23, 2026, and the question asked is whether each listed rule should be kept, amended or rescinded to reduce the burden on small entities. 8
Finally, the Commission gave notice on October 22 that it intends to cancel the registrations of transfer agents it believes are no longer in existence or have stopped acting as transfer agents. The order can issue any time after December 1, 2026. A listed agent that is still operating has that window to say so. 9
FDA
The first antisense drug for hepatitis B
The FDA approved Hibsago, or bepirovirsen, on October 20 for adults with chronic hepatitis B who have no cirrhosis. It is the first antisense oligonucleotide approved for the disease. The drug works by targeting the genetic instructions the virus uses to copy itself and make its proteins. 10
The eligible population is narrow and defined by lab values: patients on hepatitis B antiviral therapy for at least six months, with suppressed virus levels and surface antigen of 3,000 IU/mL or less on an authorized test. The approval came to GSK, with the Roche Elecsys HBsAg II quant II assay authorized as a companion diagnostic. 10
In two placebo-controlled trials, 24% of patients given Hibsago met the requirements to stop their existing medicine. Nobody on placebo did. Twenty-four weeks after all treatment stopped, 19% of the Hibsago group still had the virus under control with no detectable surface antigen. 10
The drug carries a boxed warning for serious liver reactions and low platelet counts, which raise the risk of dangerous bleeding. Warnings also cover worsening kidney function, inflammatory reactions such as vasculitis, and administration errors. It is injected under the skin for up to 24 weeks, alongside existing antiviral treatment that continues for at least 24 weeks after the last Hibsago dose. 10
The label covers stopping therapy, where existing hepatitis B drugs keep the virus suppressed for as long as they are taken. One patient in four reached the point where treatment could end. GSK shares closed at $50.63 on October 20, up 2.37% on 5.5 million shares. 24
Software that ships with the pill
The FDA finalised guidance on October 20 for software that a drug sponsor distributes for use with a prescription medicine. The guidance finalises a September 2023 draft and answers three questions: when app content counts as FDA-required labeling, when an app belongs in the prescribing information, and what a sponsor must submit. 11
The dividing line is whether the software is tied to a device. An app paired with a device, such as one working with an asthma inhaler, generally should be described on the drug's official label, because the software shapes how the medicine is used. 11
A standalone app, such as a symptom tracker or a dose reminder, reaches the label only if the sponsor shows it is essential to safe and effective use or delivers a meaningful clinical benefit. Content that a companion app displays to users will usually be treated as promotional material, on the same footing as other drug advertising. 11
The operational consequence lands on medical, legal and regulatory review. Promotional treatment pulls app copy into the same review and submission discipline as advertising, and it makes version control part of the label question. The announcement itself was published in the Federal Register on October 21. 25
A once-weekly insulin for children
On October 23 the FDA approved Awiqli, or insulin icodec-abae, for patients aged 10 and older with type 2 diabetes, injected once a week. The application belongs to Novo Nordisk Inc. under BLA 761326, and the drug was already approved for adults earlier this year. This is the first once-weekly insulin cleared for children. 1213
The pediatric basis is thin by design. A single-dose study measured blood levels in 18 patients aged 10 and older, and pharmacometric modelling projected that levels match adults after the first few doses. The approval notice describes no efficacy trial in children. 13
Safety looks like other insulins: hypoglycaemia, allergic reactions, injection site reactions, itching, rash, swelling and weight gain. The label also warns about medication errors and accidental overdose, and tells patients to check the dose on the Awiqli FlexTouch pen before each injection because dosing differs from other insulins. 13
Novo Nordisk shares closed at $39.05 on October 23, down 0.96% on 9.2 million shares. A single approval moves a share that size by little, and the rest of that day's trading sits inside the number. 26
Toxic metals, chemical hazards and cosmetics
Three guidance documents landed on October 23, and the two food ones share a subject: what industry must control and document before a hazard reaches a consumer.
The first sets draft action levels for cadmium in processed food for babies and young children under two, in Docket FDA-2025-D-4023. Action levels are the agency's enforcement thresholds, and this document is aimed at levels it considers achievable across the category. Comments close December 22, 2026. 14
The second adds chapter 12 to the multichapter draft guidance on hazard analysis and risk-based preventive controls for human food. The new chapter covers control of chemical hazards, which is the category cadmium falls into. Comments close January 21, 2027. 15
Manufacturers with a food safety plan under the preventive controls rule should read these together. One publishes the threshold for a specific contaminant; the other says how chemical hazards are meant to be identified, controlled and verified in the plan that covers it.
The third is the final question-and-answer guidance on mandatory cosmetics recalls, which finalises a draft published in December 2025. It sets out the criteria, process and expectations the agency applies when it orders a recall of a cosmetic product. 16
Cosmetics brands and contract manufacturers that have treated recalls as voluntary should read the document with their quality agreements open. The guidance assumes a written procedure that names who decides, who notifies the agency, and how a recall is traced and closed out.
Also on the FDA docket
The FDA launched the Neuroscience Advancement and Innovation Nexus on October 22, a program drawing on the drug, biologic and device centers at once. Its first initiative, the Alzheimer's Prevention Accelerator, will look at trial populations, stage-appropriate endpoints and how to show that a product delays cognitive decline. Sponsors of prevention candidates should watch that work, because it will set the evidence bar they will be measured against. 17
Ten warning letters were posted on October 20, with issue dates running from September 28 to October 14. Baxter International and SnugZ USA were cited for current good manufacturing practice findings in finished pharmaceuticals, as were Zhejiang Gaorong Cosmetic, Signature Formulations and Rohto Pharmaceutical, the last with unapproved-new-drug findings as well. 18
Olympus Medical Systems drew device quality system findings. Tides Medical was cited on investigational device exemptions and premarket approval. Psyched Wellness drew a dietary supplement adulteration finding, and two tobacco retailers, snuskompagniet.com and snusi.net, were cited under the Tobacco Control Act. 18
A final guidance published October 20 tells manufacturers and distributors of new dietary ingredients what identity and safety information a notification should contain. The document answers the questions that come up most often in those submissions. 19
FTC
A passport site dressed as the State Department
The FTC sued GovAssist LLC, Entry LLC and Scott Zuckerman on October 22 in the District of Puerto Rico. The three ran websites including GovAssist.com, Entry.com and IVS.us offering passport and visa services while presenting themselves as the federal government or as affiliated with it. 20
The mechanics are a paid-search story. The defendants bought Google ads on terms such as "apply for a new passport" and "passport renewal online," so their pages appeared where travellers expected the State Department. They promised passport services they could not deliver, including direct issuance. 20
They also seeded fake positive reviews to hold up a high Trustpilot rating. The complaint alleges violations of the FTC Act, the Impersonation Rule and the Gramm-Leach-Bliley Act. Zuckerman, the owner of both companies, was operating under a prior FTC order from a stalkerware case. The Commission vote was 2-0. 20
A $106.8 million judgment and a lifetime ban
A federal court entered a $106.8 million default judgment on October 14 against Accelerated Debt Settlement Inc., ADS Resolve LLC, Financial Solutions Group LLC, Unified Capital Services LLC, Mediwerks, Resolution Specialists LLC and Futura Capital. The order bans the companies and the individual defendants from the debt relief industry. The FTC announced it on October 22. 21
The scheme targeted seniors and veterans, with operators posing as banks, credit card companies and government agencies. They promised debt reductions of 75% or more and collected illegal advance fees, working through telemarketing, direct mail and online ads. A court halted the operation in July 2025 at the Commission's request. 21
The bans run wider than debt relief. The defendants may not impersonate any government entity, business or person, may not telemarket, and may not misrepresent cancellation or refund policies, a provider's expertise, or a consumer's ability to improve a credit record. Stipulated orders against three individuals, Jeffrey Lakes, Elizabeth Reaney and Robert Knechtel, were filed on October 22. 21
Publicis, LiveRamp and five years of conditions
The FTC's consent order allowing Publicis Groupe to buy LiveRamp for $2.2 billion was announced on October 19, and its analysis was published for comment on October 23. Comments close November 23, 2026. 22
The complaint alleged that combining Publicis, the largest US media agency group, with LiveRamp, the leading data connectivity provider, would hurt competition in media agency services and audience data services. The theory was foreclosure: Publicis could push LiveRamp customers toward its own agency business. 27
The order runs for five years from closing. Publicis and LiveRamp must give non-discriminatory access to LiveRamp's standalone products on fair and reasonable terms, and may not deny, degrade or delay a customer's access. Firewalls must keep Publicis out of LiveRamp customer data and confidential business information. 27
An independent auditor must check compliance every six months for the first two years, then annually for three more. LiveRamp customers can request their own audit of how Publicis handles their data, and disputes unresolved after 30 days go to third-party mediation. The Commission vote was 2-0. 27
A petition about penny auctions
The FTC published a rulemaking petition from Jason Plotzker on October 21 and invited comment by November 20, 2026. The petition asks for rules on deceptive or materially misleading price advertising by penny auction and pay-per-bid auction operators, in Docket FTC-2026-1618. 23
Publication starts a 30-day public record. The Commission will decide afterwards whether to grant the petition in whole or part, and it may find the petition insufficient to start a rulemaking at all. 23
Deadlines to calendar
| Date | Item | Action |
|---|---|---|
| Oct. 27, 2026 | SEC Small Business Capital Formation Advisory Committee meeting | Attend, in Washington or by webcast. 28 |
| Oct. 30, 2026 | FTC petition for rulemaking of Malik Tony Singleton | Comment. 29 |
| Nov. 9, 2026 | FDA request for information on deceased donor islet cells | Comment. 30 |
| Nov. 15, 2026 | FDA advisory committee consumer representative nominations | Nominate, for first consideration. 31 |
| Nov. 20, 2026 | FTC petition for rulemaking of Jason Plotzker | Comment. 23 |
| Nov. 20, 2026 | FDA request for information on ibogaine trial design | Comment. 32 |
| Nov. 23, 2026 | FTC consent order in Publicis and LiveRamp | Comment. 22 |
| Nov. 23, 2026 | SEC section 610 rule review list | Comment, File No. S7-2026-37. 8 |
| Nov. 23, 2026 | FDA draft guidance on food traceability enforcement policy | Comment. 33 |
| Nov. 24, 2026 | FDA draft guidance on robotically-assisted surgical devices | Comment. 34 |
| Nov. 25, 2026 | FDA public meeting on reauthorization of the Biosimilar User Fee Act | Comment or attend. 35 |
| Nov. 30, 2026 | FTC Rule on Impersonation of Government and Businesses | Comment. 36 |
| Nov. 30, 2026 | FDA advisory committee scientific and technical member nominations | Nominate, for first consideration. 31 |
| Dec. 1, 2026 | SEC transfer agent registration cancellations | Listed agents still operating must tell the Commission before this date. 9 |
| Dec. 4, 2026 | SEC interval fund modernization and multiple share class proposal | Comment, File No. S7-2026-34. 6 |
| Dec. 6, 2026 | FDA public meeting on lot-level food traceability | Comment or attend. 37 |
| Dec. 7, 2026 | FTC and USDA agricultural equipment request for information | Comment. 38 |
| Dec. 7, 2026 | FDA direct final rule on nonclinical testing terminology | Comment on the companion proposed rule. 39 |
| Dec. 11, 2026 | FDA docket on the Rare Disease Framework Initiative | Comment. 40 |
| Dec. 14, 2026 | SEC cross-trading proposal | Comment. 41 |
| Dec. 22, 2026 | FDA draft guidance on cadmium action levels in food for children under two | Comment. 14 |
| Jan. 21, 2027 | FDA draft chapter 12 on control of chemical hazards | Comment. 15 |
Where these matters stand
The SEC's examiner priorities are the only prospective document in the SEC block, and they change what the rest of the year looks like for registered firms. The custody and Regulation S-ID failures at TAG Associates sit squarely inside that frame: a written program without an operating review is the kind of finding a risk-based examination is built to surface.
The two settled fraud cases and the Conde judgment share a structure. In each, an operator showed retail investors a picture of performance the records did not support, then kept raising money after the gap opened. Patel used account statements, Berland and Scalzo used revenue projections, Conde used trades that canceled each other out.
The FDA's week splits in two. The two approvals answer different evidence questions. Awiqli reached children through a single-dose blood-level study in 18 patients plus modelling. Hibsago's trials turned on how many patients could stop all treatment, a harder test than suppressing the virus. The guidance documents are about documentation: which hazards a food safety plan must control, what a notification must contain, and when app copy becomes advertising.
Two of the four FTC matters turn on companies presenting themselves as something they are not: a passport site dressed as the State Department and debt relief firms posing as banks, both with invented or impossible promises behind them. The Publicis order is a merger condition with a five-year compliance calendar attached. The penny-auction petition asks the Commission to write price-advertising rules for penny auctions and pay-per-bid auctions.
Only two companies named this week had a product event of their own to trade on. GSK closed up 2.37% on its approval day and Novo Nordisk closed down 0.96% on its own. Both figures cover one session in a large-cap share, where a single label change moves the price by little.
References
- 1
- 2
- 3
- 4
- 5
- 6Interval Fund Modernization, correction
federalregister.gov
- 7
- 8List of rules to be reviewed pursuant to the Regulatory Flexibility Act
federalregister.gov
- 9Notice of intention to cancel registrations of certain transfer agents
federalregister.gov
- 10
- 11
- 12BLA 761326 approval letter, Novo Nordisk Inc.
accessdata.fda.gov
- 13
- 14
- 15Hazard analysis and risk-based preventive controls for human food
federalregister.gov
- 16Questions and answers regarding mandatory cosmetics recalls
federalregister.gov
- 17
- 18FDA warning letters index
fda.gov
- 19New dietary ingredient notifications and related issues
federalregister.gov
- 20
- 21
- 22Publicis and LiveRamp, analysis of proposed consent order
federalregister.gov
- 23Petition for rulemaking of Jason Plotzker
federalregister.gov
- 24GSK historical daily prices
stockanalysis.com
- 25Regulatory considerations for prescription drug use-related software
federalregister.gov
- 26Novo Nordisk historical daily prices
stockanalysis.com
- 27
- 28
- 29Petition for rulemaking of Malik Tony Singleton
federalregister.gov
- 30Improving patient access to deceased donor islet cells
federalregister.gov
- 31
- 32Design and safety considerations for clinical trials involving ibogaine
federalregister.gov
- 33Requirements for additional traceability records for certain foods
federalregister.gov
- 34Robotically-assisted surgical devices draft guidance
federalregister.gov
- 35Reauthorization of the Biosimilar User Fee Act
federalregister.gov
- 36Rule on Impersonation of Government and Businesses
federalregister.gov
- 37Challenges and solutions in lot-level food traceability
federalregister.gov
- 38
- 39Nonclinical testing terminology
federalregister.gov
- 40Fit-for-purpose Rare Disease Framework Initiative
federalregister.gov
- 41Investment Company Cross Trading
federalregister.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.